COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B2JZ
|
|||
| Drug Name |
K11777
|
|||
| Synonyms |
N-methyl-piperazine-Phe-homoPhe-vinylsulfone-phenyl
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Middle East Respiratory Syndrome (MERS) | Preclinical | [1], [2] | Severe acute respiratory syndrome (SARS) | Preclinical | [1], [2] |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| PubChem Substance ID | ||||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN cathepsin L (CTSL) | Target Info | Blocker | [1], [2] |
| K11777 can inhibit cathepsin L which is involved in the endosomal pathway and block CoVs entry to exhibit broad-spectrum activities against enveloped RNA viruses such as CoVs (SARS-CoV, MERS-CoV). | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
| 2 | Protease Inhibitors Targeting Coronavirus and Filovirus Entry. Antiviral Res. 2015 Apr;116:76-84. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.